glaucoma | GenomeWeb

glaucoma

Researchers linked loci near three genes, including one involved in limiting oxidative damage, to primary open-angle glaucoma susceptibility.

Through genetic association and functional studies, researchers from the University of California, San Diego found that risk variants in SIX6 and p16INK4a are associated with senescence of retinal ganglion cells.

NEW YORK (GenomeWeb) – Quark Pharmaceuticals announced this week that it has dosed the first patient in a Phase IIa study of QPI-1007, its siRNA-based treatment for glaucoma.

With positive phase II data on its siRNA-based glaucoma treatment in hand, Spanish RNAi drug developer Sylentis is preparing to move into phase IIb study next year, with a pivotal trial possible by 2015, according to a company official.

NEW YORK (GenomeWeb News) –Researchers at the University of California, San Diego have won $6.4 million in funding from the National Eye Institute to investigate the genetic basis of glaucoma, with a particular focus on how the disease arises in people of African descent.

The National Institutes of Health this month awarded nearly $2 million in grant funding to support eight research projects investigating the roles of microRNAs in a variety of diseases and biological functions including psychiatric disorders, immune function, glaucoma, and cancer

This article has been updated to correct details regarding SYL1001's development timeline.

Quark Pharmaceuticals said this week that it is has assumed responsibility for conducting a phase IIa trial of its investigational RNAi-based treatment for open-angle glaucoma after amending a licensing deal for the drug with Pfizer.

Quark Pharmaceuticals last week announced “favorable” interim results from a phase I trial of its siRNA-based ocular neuroprotectant QPI-1007, showing the drug may improve the vision of patients with a rare eye condition.

Pages

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.